Study drug KC1036 for advanced digestive cancers
Treatments studied
Part of Digestive system clinical trials.
This early-phase study tests whether KC1036 can treat advanced digestive system cancers that have come back or spread after standard treatment. It may help people by shrinking tumors or slowing growth, and it will also check safety and side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed digestive system cancer (proven by a biopsy or cell test).
- Your cancer is advanced, cannot be fully removed, and has not responded to usual treatment.
- You feel well enough to do daily activities (performance score 0 or 1).
- You’re expected to live more than 12 weeks, and your BMI is at least 18.
- Your blood counts, kidneys, and liver tests are within allowed ranges.
- You can safely participate and sign informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a new drug, KC1036, to standard chemotherapy options for people with advanced esophageal squamous cell cancer that has progressed after immunotherapy and at least one chemo. It aims to see if KC1036 works better or has fewer side effects.
This trial tests a new drug called KC1036 combined with standard immunotherapy and chemotherapy for people with advanced esophageal cancer that has not been treated before. The goal is to see if this combination can help shrink tumors and improve outcomes.
This trial tests an experimental drug called KM602 for people with advanced solid tumors that have stopped responding to standard treatments, particularly melanoma and non-small cell lung cancer. It aims to see if the drug is safe and effective in shrinking or controlling tumors.
This study is testing an experimental medication called GNC-077 that may help treat certain advanced cancers, especially those in the digestive system. The goal is to see if the drug is safe and how well it works in people who have already tried standard treatments.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This Phase 1 trial studies how a new medicine (KC1036) works and how safe it is for people with advanced solid cancers that have grown despite standard treatments. It may help future patients by showing whether the drug can control cancer in difficult-to-treat cases.
Hear when a new Digestive System Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.